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Abstract
Background Polypharmacy is a growing health concern for older adults and is associated with poorer clinical outcome. 
Objective This study aim is to investigate the association between polypharmacy and impairment in cognitive, physical 
and emotional capability controlling for the confounding effect of co-morbidities. Setting The Aberdeen 1936 Birth Cohort 
from 1999 to 2004. Method Recruited were 498 dementia free participants around 64 years old and recruited into wave one. 
Linear regression and structural equation models were used. Models were adjusted for the effect of age, gender, childhood 
IQ, education and Body Mass Index. A triad of impairment was defined as a composite measure of impairment in cogni-
tive, physical and emotional function. Main outcome measure The relationships between polypharmacy, co-morbidity and 
triad of impairment. Results The prevalence of polypharmacy was 12.3% in this relatively healthy sample. Polypharmacy 
was significantly associated with increased impairment in cognitive, physical and emotional ability (β = 3.6, p = 0.003) after 
controlling for the effect of comorbidities and other confounding variables. As expected, higher childhood IQ and educational 
achievement had protective effects against impairment while higher comorbidity score and Body Mass Index were associ-
ated with increased impairment in this population. Conclusions The independent association of polypharmacy and reduced 
cognitive, physical and emotional capability makes this a promising target for predicting and potentially reducing the risk 
of impairment and associated healthcare costs in older adults. Longitudinal studies are required to investigate the underlying 
mechanisms for the observed relationships further.
Keywords Cognitive impairment · Emotional impairment · Observational cohort study · Older adults · Physical 
impairment · Polypharmacy · United Kingdom
Impacts on practice
• Considering number of medications could improve our 
understanding of functional health status in older adults.
• Interventions to reduce inappropriate polypharmacy 
might improve cognitive, physical and emotional capa-
bility and outcomes in the elderly.
Introduction
Aging is associated with the accumulation of multiple 
chronic diseases and increased risk of varying degrees of 
physical, cognitive and emotional impairment [1]. Prescrib-
ing medicines is still the most common form of medical 
intervention to manage chronic diseases and many older 
people will take several prescription medications. Polyp-
harmacy, which is usually defined as taking five or more 
medications [2], is a common consequence of the increasing 
co-morbidity burden seen in older age. Polypharmacy could 
cause increased side effects, such as falls and harmful medi-
cine interactions in older people [3]. Polypharmacy may also 
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increase the risk of cognitive and physical impairment and 
frailty, in elderly people independently of other risk factors 
[4–6].
Decline in cognitive and emotional function frequently 
co-exists with physical dysfunction in late life [7, 8]. Com-
mon pathological pathways such as macroinfarcts and nigral 
neuronal loss in the brain, hormonal changes and inflamma-
tion may explain the co-occurrence of mental and physical 
impairment in older adults [9, 10]. Investigating the shared 
impairment in cognitive, physical and emotional function, 
or the “triad of impairment” (TOI) [11–13], is an approach 
to quantifying such decline. This approach could make these 
complex inter-relationships between impairment in multi-
ple domains more accessible for clinicians to quantify and 
address in treatment and prevention strategies.
Aim of the study
Here we examined associations between polypharmacy 
and TOI. We controlled this association for the potentially 
confounding effects of early-life predictors of cognitive and 
emotional impairment, such as childhood IQ and education 
[12], and late-life predictors of physical impairment, such 
as co-morbidities and BMI [6, 14]. We hypothesized that 
polypharmacy would be associated with increased impair-
ment in a normal aging population sample independent of 
the effect of chronic disorders.
Ethics approval
Approval was obtained from the NHS Grampian 
Local Research Ethics Committee with reference 
03/0151(abc1936).
Methods
Population
The study population was drawn from members of the Aber-
deen 1936 Birth Cohort (ABC1936), established in 1999 in 
Aberdeen, Scotland. This cohort had been fully described 
elsewhere [15]. In brief, mental ability of all participants 
was measured with the Moray House Test (MHT) at age 
11  year as part of the Scottish Mental Survey of 1947 
(SMS 47). 498 dementia free survivors of the SMS 47 aged 
around 64 year (between 63 and 68 year) were recruited 
into wave 1 of the ABC1936 cohort from 1999 to 2004. 
Complete neuropsychological, physical examination and the 
Short-Form-36 (SF36) health survey data were available for 
341 participants and included in the current study.
Participants’ health details
Participants were asked about their current medications 
with the questions “what medications are you on?” and 
“Could you please show me your latest prescription(s)?” 
We classified medications based on their therapeutic cat-
egory using the British National Formulary (BNF). We 
also counted combined formulation based on their separate 
components, for example Co-codamol was counted as par-
acetamol and codeine phosphate.
We asked for details of current or previous diseases or 
health issues. These were recoded using the International 
Statistical Classification of Diseases and Related Health 
Problems 10th Revision (ICD-10) [16]. After recoding, 
chronic conditions were counted and weighted based 
on the Charlson’s co-morbidity index. Briefly, eighteen 
chronic conditions were identified. Myocardial infarc-
tion, congestive heart failure, peripheral vascular disease, 
cerebrovascular disease, dementia, chronic obstructive 
pulmonary disease, connective tissue disease, ulcer dis-
ease and diabetes were counted and weighted as 1. Hemi-
plegia, moderate or severe renal disease, diabetes with 
end organ damage, any tumor, leukaemia and lymphoma 
were weighted as 2. Moderate or severe liver disease were 
weighted as 3 and metastatic solid tumor and AIDS/HIV 
were weighted as 6. A score of co-morbidities was calcu-
lated based on this index [17]. Participants’ co-morbidity 
status was classified as 0 for not ill; 1 and 2 for mildly to 
moderately ill; and 3 or more for severely ill.
Education achievement
Having no qualifications was coded 1; lower and higher 
leaving certificates were coded 2 and 3 respectively; Scot-
tish vocational certificate coded 4; ordinary grades coded 
5; Higher/Advanced level were coded 6; undergraduate 
and postgraduate degrees were coded 7 and 8 respectively 
and a professional or higher degree coded as 9 [15]. Edu-
cational achievement was used as a possible mediator of 
TOI in the model.
Neuropsychological and cognitive tests
Cognitive ability of the participants at age 64 year was 
measured using four different tests including: Auditory 
Verbal Learning Test (AVLT), assessing verbal mem-
ory [18]; Digit Symbol Score (DS), a processing speed 
measure [19]; Block Design Score (BLK), as a spatial 
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ability measurement [19] and Raven’s Progressive Matri-
ces (RPM), a non-verbal reasoning measure of fluid intel-
ligence [20]. Childhood mental ability at age 11  year 
(± 6 months) (MHT) was assessed by the Scottish Council 
for Research in Education in 1947.
Physical and mental health examination
The SF36 health survey is a self-reported multi-dimensional 
health related quality of life questionnaire and consists of 
eight different domains [21]. We used the mean of Physical 
Functioning (PF), Role-Physical (RP), Bodily Pain (BP) and 
General Health (GH) domains as a self-assessed subjective 
measure of physical health of the participants. The mean 
of Vitality (VT), Social Functioning (SF), Role-Emotional 
(RE) and Mental Health (MH) domain scores were used as 
a measures of mental health. Walk time, the time in seconds 
it took participants to walk 6 m, normalised for height, and 
HADS depression and anxiety scores were analysed as indi-
cators of physical and emotional function respectively.
Triad of impairment
We used cognitive ability test results, and physical and 
mental health examinations to calculate our outcome of 
interest, TOI, using Principal Component Analysis (PCA). 
We reduced our variables of interest in two steps to obtain 
a single representative value for impairment in cognitive, 
physical and emotional function. We used the same method 
to calculate TOI as described previously [12] with some 
modifications. Briefly, the cognitive test scores, AVLT, DS, 
BLK and RPM, were used to calculate general cognitive fac-
tor (gf). HADS anxiety and depression score and the SF36 
mental health domain scores were used to derive an emo-
tional impairment factor (ef). A physical impairment factor 
was obtained using PCA on walk time and mean of the SF36 
physical health domains (pf). In the second step, PCA was 
performed on gf, ef and pf to calculate the component TOI 
as an overall indicator of impaired cognition, physical and 
emotional function.
Statistical analysis
Independent sample t-tests (continuous normally distrib-
uted variables) and Kolmogorov–Smirnov tests (non-nor-
mally distributed variables) were used to compare variables 
between genders. Due to a non-normal distribution TOI was 
log transformed before use as a dependant variable in the 
regression models. Statistical models were developed in two 
steps. First, a multiple regression model was used to exam-
ine associations between polypharmacy and TOI adjusting 
for co-morbidity score (IBM SPSS, 24). Age, gender, child-
hood IQ, education and BMI were included as co-variates of 
interest in the final model. Next, Structural Equation Models 
(SEM) were designed (IBM, AMOS, 24). We defined TOI 
in the SEM as a latent variable which is obtained from gf, 
ef, and pf. This approach enabled us to examine direct and 
indirect (mediating) contributions of medications and co-
morbidity to latent TOI as well as to individual domains of 
latent TOI. We analysed number of medications used as a 
continuous variable in the SEM. This approach accounts for 
linear effects of number of medications (e.g. from 1 to 4) and 
a possible dose response relationship which would be lost 
using a binary classification system [22]. The goodness of fit 
was assessed according to the combined value of Compara-
tive Fit Index (CFI) ≥ 0.95 and Root Mean Square Error of 
Approximation (RMSEA) ≤ 0.06 as an acceptable fit of the 
model to the data [23]. We examined modification indices 
in order to introduce new plausible paths to the model to 
improve model fit. The significance level for all relationships 
was α = 0.05.
Results
Gender differences
A summary of overall demographic, cognitive, physical 
and health data are shown in Table 1. Female participants 
scored higher on AVLT and DS tests whereas male partici-
pants performed better at BLK and walk time. In addition, 
female participants reported higher levels of anxiety (HADS 
anxiety) compared to male participants. TOI did not differ 
between genders.
Extraction of derived physical, emotional 
and cognitive factors and TOI
Results of the PCA, percentage of total variance explained 
by the new extracted component and component loading for 
the variables are given in Table S1 Supplementary data. The 
first un-rotated principal component (gf) described 55% of 
the shared variance between cognitive tests. The component 
“ef” explained 66% and the component “pf” accounted for 
68% of the total variance. The component loadings for gf, ef 
and pf were comparable in the new calculated component, 
TOI (Table S1, Supplementary data).
Association between polypharmacy and TOI
Table 2 shows the relationship between polypharmacy and 
TOI adjusting for co-morbidity score and other confound-
ing variables. Polypharmacy was associated with increased 
TOI even after adjusting for co-morbidity score and other 
confounders (β = 3.6, p = 0.003). As expected increased co-
morbidity score was associated with increased TOI and this 
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effect is stronger for the severely ill participants (β = 5.3 and 
β = 2.5 for severely and mildly to moderately ill respectively, 
not ill set to 0 as control, p < 0.01).
Lower childhood IQ, lower educational qualification and 
higher BMI were associated with increased impairment in 
cognitive, physical and emotional capability (Table 2).
Structural equation modelling
Figure 1 shows the path diagram and the results of the SEM. 
Pf had the highest loading factor of 0.91 in the new calcu-
lated component, TOI. The model had good fit indices as 
CFI = 0.993 and RMSEA = 0.048.
As expected, co-morbidity contributed significantly 
to mean number of medications (standardised β = 0.54, 
p < 0.001). Mean number of medications contributed 
directly to latent TOI (standardised β = 0.27, p < 0.001). Co-
morbidity had a direct effect on TOI (standardised β = 0.24, 
p < 0.001). The indirect effect of co-morbidity on TOI was 
mediated through increased number of medications (stand-
ardised β = 0.15). The standardised total contribution of 
increased co-morbidity to TOI was β = 0.39. After an initial 
analysis, modification indices indicated that a new correla-
tion between r1 and r5 would improve model fit (Fig. 1). 
This correlation (correlation coefficient = 0.18, p = 0.004) 
suggests that an individual’s emotional impairment and 
mean number of medications error term could be affected 
by the same unmeasured common factor.
We then excluded participants that reported any affective 
disorders (e.g. depression and anxiety) and/or were taking 
any related medications such as selective serotonin reuptake 
inhibitors, tricyclic antidepressants and benzodiazepines to 
eliminate the effects of these disorders on the relationships 
described in our model. We then replicated the analysis in 
the remaining 303 participants and found the same results as 
for the whole sample. The results of this model are available 
in the Supplementary data (Figure 2S, Supplementary data).
Table 1  Characteristic of 
study population, comparison 
in predictors and outcome 
variables by gender
*p ≤ 0.05, **p ≤ 0.001
Characteristics All
N = 341
Female
N = 171
Male
N = 170
Age mean (SD) 64.8 (0.8) 64.9 (0.8) 64.7 (0.8)
Number of medications n (%)
0 104 (30.5) 49 (28.6) 55 (32.3)
1–4 195 (57.2) 97 (56.7) 98 (57.6)
≥ 5 (polypharmacy) 42 (12.3) 25 (14.6) 17 (10.0)
Charlson’s co-morbidity index median (range) 1 (0–8) 1 (0–8) 1 (0–4)
Charlson’s co-morbidity index n (%)
0 (not ill) 147 (43.1) 68 (39.8) 79 (46.5)
1–2 (mildly to moderately ill) 166 (48.7) 84 (49.1) 82 (48.2)
≥ 3 (severely ill) 28 (8.2) 19 (11.1) 9 (5.3)
Childhood IQ mean (SD) 44.2 (12.3) 45.2 (12.0) 43.2 (12.5)
Education mean (SD) 3.3 (2.3) 3.4 (2.3) 3.2 (2.3)
BMI mean (SD) 27.0 (4.2) 27.1 (4.8) 26.9 (3.5)
Cognitive mean (SD)
Ravens progressive matrices (RPM) 36.8 (8) 36.6 (8.1) 36.9 (7.8)
Auditory verbal learning test (AVLT) 59.6 (12.8) 64.4 (11.6)** 54.8 (12.1)**
Digit symbol (DS) 44.9 (11.3) 47.1 (11.5)** 42.7 (10.6)**
Block design test (BLK) 25.2 (8.4) 23.4 (8.3)** 27.0 (8.2)**
Physical mean (SD)
SF36 mean of physical health 75.1 (21.4) 75.9 (20.0) 74.4 (22.8)
6 m walk time test (s) (WTM) 3.0 (0.7) 3.3 (0.7)** 2.9 (0.6)**
Emotional mean (SD)
SF36 mean of mental health 81.9 (17.1) 81.7 (16.8) 82.0 (17.5)
HADS anxiety 5.8 (3.1) 6.4 (3.2)** 5.2 (2.8)**
HADS depression 2.9 (2.3) 3.0 (2.4) 2.8 (2.2)
Triad of impairment mean (SD) 69.1 (8.3) 69.8 (8.4) 68.4 (8.1)
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Discussion
Interpretation of the results
Here we showed that polypharmacy was associated with 
increased impairment in cognitive, physical and emotional 
capability in a dementia-free aging sample of the general 
population. Increased co-morbidity and a high BMI were 
also related to increased impairment in this population. As 
expected, higher childhood IQ and educational qualification 
were negatively associated with TOI.
The most striking finding in this study was the associa-
tion of polypharmacy and increased impairment in late 
life, independent of chronic diseases and other possible 
risk and protective factors. This finding demonstrates that 
considering number of medications taken, in addition to 
morbidity measurements, would improve our understand-
ing of functional health status in older adults.
Our findings are consistent with the longitudinal Brit-
ish birth cohort study that found a significant relation-
ship between polypharmacy and cognitive and physical 
impairment. In this study stronger negative associations 
were seen in participants with longstanding polypharmacy, 
suggesting a cumulative, dose-dependent association, 
where dose is the number of prescribed medications [6]. 
It is plausible that number of medications plays a causal 
role in increasing TOI in older adults. Recently the role of 
polypharmacy in increasing risk of frailty and impairment 
has been of much research interest. Recent studies have 
found that polypharmacy is associated with higher preva-
lence of frailty due to medicine interactions, malnutrition 
and more severe adverse effects in older people [3, 4, 24]. 
Further research should establish whether a higher TOI 
score is an early manifestation of frailty development and 
Table 2  Regression models examine the effect of polypharmacy on TOI score (TOI range: 48.8–96.4, increased in the score means increased 
impairment, n = 341)
a Adjusted for co-morbidity score
b Adjusted for co-morbidity score, age, gender, childhood IQ, education and BMI
Characteristics Unadjusted model Adjusted  modela Adjusted  modelb
β (95% CI) p value β (95% CI) p value β (95% CI) p value
Intercept 68.3 < 0.001 66.3 < 0.001 87.3 0.003
0–4 medicines 0 0 0
≥ 5 medicines (polypharmacy) 5.9 (3.3, 8.6) < 0.001 4.3 (1.5, 7.0) 0.002 3.6 (1.2, 6.0) 0.003
Co-morbidity score
0 – 0 0
1–2 (mildly to moderately ill) – 3.7 (1.9, 5.4) < 0.001 2.5 (0.9, 4.1) 0.002
≥ 3 (severely ill) – 5.7 (2.3, 9.1) 0.001 5.3 (2.3, 8.3) 0.001
Age – – − 0.2 (− 1.1, 0.6) 0.565
Gender
Male – – 0
Female – – 1.5 (− 0.1, 2.9) 0.046
Childhood IQ – – − 0.2 (− 0.3, − 0.1) < 0.001
Education – – − 0.8 (− 1.2, − 0.4) < 0.001
BMI – – 0.2 (0.1, 0.4) 0.007
R2 0.056 0.113 0.353
Adjusted  R2 0.053 0.105 0.337
Fig. 1  Path diagram of hypothesised model (n = 341). Solid lines rep-
resent hypothesised path and dash line represent path added to the 
model based on the modification indices. ef emotional impairment 
factor, pf physical impairment factor, gf cognitive ability factor. All 
the standardised regression weights represents in the diagram are 
statistically significant (p < 0.001). r1 to r5 are residual (error) terms 
within the model
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if polypharmacy is associated with an increased preva-
lence of frailty syndrome in this population. It is notable 
that polypharmacy could be both necessary and rational 
in some older adults with multimorbidity and frailty. It is 
therefore important to distinguish and consider appropri-
ate from inappropriate polypharmacy when discussing its 
outcomes [2].
Although the co-morbidity had a strong positive effect 
on number of medications (β = 0.54, p < 0.001), we found 
that number of medications and emotional impairment could 
possibly be affected by the same unmeasured factor. This 
interesting finding could suggest that poorer emotional capa-
bility is associated with increased use of general and men-
tal health services, and thus increased medication use [25]. 
Increased risk of mental health disorders, such as depres-
sion and anxiety, might also lead to higher medication use. 
However, our model finds that this relationship is significant 
in participants that did not report any neurotic disorder or 
related medicine use (Figure 2S, Supplementary data). A 
possible explanation could be that undiagnosed depression 
and anxiety increases self-medication in older people [e.g. 
taking of over the counter (OTC) medications] and increases 
the prevalence of polypharmacy [26].
Strengths and weaknesses
Although physical, emotional and cognitive impairment 
often co-exist in the elderly and recent studies showed that 
they may have shared origins [9, 10, 27], their co-occurrence 
is rarely investigated [11, 12]. TOI used in this study ena-
bled us to study the co-occurrence of impairment in multi-
ple domains, including physical deficits. The key strengths 
of our study include using a wide range of predictors of 
cognitive and physical impairment from early-life to late 
mid-life. To test possible causal relationships between these 
inter-related factors we used robust statistical methods and 
modelling. Improving our understanding about how these 
predictors are associated with TOI allows us to identify tar-
gets that might reduce impairment in older adults.
Weaknesses are the relatively small sample size and the 
use of self-reported medications and description of diseases 
which could introduce recall bias. However, the participants 
were relatively young and dementia-free when data were 
collected which would reduce the likelihood of misclassi-
fication or under/over-estimation of these results. We also 
only measured TOI, medications and morbidities at a single 
time point. Longitudinal research is needed to understand the 
casual relationships and to make prediction of future cog-
nitive, emotional and physical function in this population.
Conclusion
Polypharmacy is associated with increased impairment in 
cognitive, physical and emotional function in older adults. 
This relationship is independent of the co-morbidity bur-
den and other confounding factors. Longitudinal studies are 
required to better understand the underlying mechanisms of 
the observed relationships in this study. Our findings suggest 
that reducing inappropriate polypharmacy is a promising 
strategy to reduce impairment in different domains in older 
adults and associated healthcare costs.
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